| Name | Verici DX |
|---|---|
| Epic | VRCI |
| Isin | GB00BM8HZD43 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.31p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.03 | Debt ratio | n/a |
| Shares in issue | 242.54 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -118.15 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -6.9 | 52-week high / low | 2.88p / 11.75p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Verici DX |
|---|---|
| Address | Avon House, 19 Stanwell Road, Penarth, Cardiff, United Kingdom, CF64 2EZ |
| Telephone | +44 (0)29 2071 0570 |
| Website | http://www.vericidx.com/ |
| Director | Position |
|---|---|
| Ms Sara Barrington | CEO |
| Mr Lorenzo Gallon | Non-Executive Director |
| Mr Erik Kristian Lium | Non-Executive Director |
| Mr James Renwick McCullough | Non-Executive Director |
| Mr Julian Baines | Non-Executive Chairman |
| Sir Ian James Carruthers | Senior Independent Non-Executive Director |
| Assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 1.97 | 2.01 | 1.77 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 3.98 | 2.79 | 2.23 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.52 | 0.66 | 0.32 |
| Cash and equivalents | 9.8 | 10.34 | 17.75 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 14.3 | 13.79 | 20.31 |
| Liabilities $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 2.25 | 1.8 | 0.68 |
| Long term liabilities | 0.54 | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2.8 | 1.8 | 0.68 |
| Net assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 11.51 | 11.98 | 19.62 |
| Equity $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.22 | 0.18 | 0.18 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -24.47 | -13.06 | -4.74 |
| Share premium account | 32.95 | 20.35 | 20.35 |
| Total equity | 11.51 | 11.98 | 19.62 |
| Income $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -11.46 | -8.33 | -4.67 |
| Pre-tax profit | -11.41 | -8.33 | -4.74 |